Despite major advances in our understanding of the alternative lengthening of telomere mechanisms in the past 2 decades, and the discovery of potential targetable vulnerabilities in cancer cells relying on ALT, these cancers still lack clinically approved treatment options. This evidence concerns the gene GPT and cancer.